Citigroup
ALLO icon

Citigroup’s Allogene Therapeutics ALLO Stock Holding History

Citigroup’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-30,000
Closed -$324K – 5762
2022
Q3 		$324K Buy
+30,000
New +$408K ﹤0.01% 3518

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Citigroup's ALLO Position: Q2 2026 in Review

Citigroup increased its Allogene Therapeutics (ALLO) stake by 46% in Q2 2026, buying an estimated $356K and bringing the position to 515,499 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3402.

Citigroup first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $5.17M in Q2 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Citigroup held 515,499 shares of Allogene Therapeutics worth $1.07M as of Q2 2026.
  • Citigroup bought 162,164 Allogene Therapeutics shares in Q2 2026, an estimated $356K.
  • Allogene Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3402 holding.
  • Citigroup first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Citigroup's Allogene Therapeutics position peaked at $5.17M in Q2 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.